167 related articles for article (PubMed ID: 38543278)
1. Weekly Oral Tenofovir Alafenamide Protects Macaques from Vaginal and Rectal Simian HIV Infection.
Massud I; Nishiura K; Ruone S; Holder A; Dinh C; Lipscomb J; Mitchell J; Khalil GM; Heneine W; Garcia-Lerma JG; Dobard CW
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543278
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
Massud I; Cong ME; Ruone S; Holder A; Dinh C; Nishiura K; Khalil G; Pan Y; Lipscomb J; Johnson R; Deyounks F; Rooney JF; Babusis D; Park Y; McCallister S; Callebaut C; Heneine W; García-Lerma JG
J Infect Dis; 2019 Oct; 220(11):1826-1833. PubMed ID: 31362305
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques.
Makarova N; Singletary T; Peet MM; Mitchell J; Holder A; Dinh C; Agrahari V; Mendoza M; Pan Y; Heneine W; Clark MR; García-Lerma JG; Smith JM; Doncel GF
EBioMedicine; 2022 Dec; 86():104338. PubMed ID: 36343572
[TBL] [Abstract][Full Text] [Related]
4. Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
Dobard CW; Peet MM; Nishiura K; Holder A; Dinh C; Mitchell J; Khalil G; Pan Y; Singh ON; McCormick TJ; Agrahari V; Gupta P; Jonnalagadda S; Heneine W; Clark MR; García-Lerma JG; Doncel GF
EBioMedicine; 2022 Dec; 86():104361. PubMed ID: 36423375
[TBL] [Abstract][Full Text] [Related]
5. Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.
Radzio J; Aung W; Holder A; Martin A; Sweeney E; Mitchell J; Bachman S; Pau CP; Heneine W; García-Lerma JG
PLoS One; 2012; 7(12):e50632. PubMed ID: 23226529
[TBL] [Abstract][Full Text] [Related]
6. Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial.
Thurman AR; Schwartz JL; Cottrell ML; Brache V; Chen BA; Cochón L; Ju S; McGowan I; Rooney JF; McCallister S; Doncel GF
EClinicalMedicine; 2021 Jun; 36():100893. PubMed ID: 34041459
[TBL] [Abstract][Full Text] [Related]
7. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling.
Rajoli RKR; Demkovich ZR; Flexner C; Owen A; Siccardi M
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423957
[TBL] [Abstract][Full Text] [Related]
8. The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques.
Daly MB; Sterling M; Holder A; Dinh C; Nishiura K; Khalil G; García-Lerma JG; Dobard C
Antiviral Res; 2021 Feb; 186():105001. PubMed ID: 33385420
[TBL] [Abstract][Full Text] [Related]
9. Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination Protects Macaques From Rectal Simian/Human Immunodeficiency Virus Infection.
Massud I; Mitchell J; Babusis D; Deyounks F; Ray AS; Rooney JF; Heneine W; Miller MD; García-Lerma JG
J Infect Dis; 2016 Oct; 214(7):1058-62. PubMed ID: 27465645
[TBL] [Abstract][Full Text] [Related]
10. Development, Characterization and In Vivo Pharmacokinetic Assessment of Rectal Suppositories Containing Combination Antiretroviral Drugs for HIV Prevention.
Jhunjhunwala K; Dobard CW; Sharma S; Makarova N; Holder A; Dinh C; Mitchell J; Wang L; Zhang J; Patel SK; Heneine W; Rohan LC
Pharmaceutics; 2021 Jul; 13(8):. PubMed ID: 34452070
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model.
Massud I; Krovi A; Nishiura K; Ruone S; Li L; Holder A; Gary J; Mills P; Mitchell J; Khalil G; Pan Y; Luecke E; Gatto G; Heneine W; García-Lerma JG; Johnson L; van der Straten A; Dobard C
J Antimicrob Chemother; 2022 Oct; 77(11):2964-2971. PubMed ID: 35913838
[TBL] [Abstract][Full Text] [Related]
12. Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques.
Massud I; Ruone S; Zlotorzynska M; Haaland R; Mills P; Cong ME; Kelley K; Johnson R; Holder A; Dinh C; Khalil G; Pan Y; Kelley CF; Sanchez T; Heneine W; García-Lerma JG
EBioMedicine; 2020 Aug; 58():102894. PubMed ID: 32707451
[TBL] [Abstract][Full Text] [Related]
13. Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates.
Pons-Faudoa FP; Sizovs A; Shelton KA; Momin Z; Niles JA; Bushman LR; Xu J; Chua CYX; Nichols JE; Demaria S; Ittmann MM; Hawkins T; Rooney JF; Marzinke MA; Kimata JT; Anderson PL; Nehete PN; Arduino RC; Ferrari M; Sastry KJ; Grattoni A
Adv Ther (Weinh); 2021 Mar; 4(3):. PubMed ID: 33997267
[TBL] [Abstract][Full Text] [Related]
14. Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.
Bekerman E; Cox S; Babusis D; Campigotto F; Das M; Barouch DH; Cihlar T; Callebaut C
J Antimicrob Chemother; 2021 Feb; 76(3):692-698. PubMed ID: 33202006
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques.
Dobard CW; Sharma S; Cong ME; West R; Makarova N; Holder A; Pau CP; Hanson DL; Novembre FJ; Garcia-Lerma JG; Heneine W
Retrovirology; 2015 Aug; 12():69. PubMed ID: 26253002
[TBL] [Abstract][Full Text] [Related]
16. Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue.
Else L; Penchala SD; Pillay AD; Seiphetlo TB; Lebina L; Callebaut C; Minhas S; Morley R; Rashid T; Martinson N; Fox J; Khoo S; Herrera C;
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745857
[TBL] [Abstract][Full Text] [Related]
17. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
[TBL] [Abstract][Full Text] [Related]
18. Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial.
Herrera C; Serwanga J; Else L; Limakatso L; Opoka D; Ssemata AS; Pillay AD; Namubiru P; Seiphetlo TB; Odoch G; Mugaba S; Seatlholo P; Alieu A; Penchala SD; Muhumuza R; Alinde B; Petkov S; O'Hagan K; Callebaut C; Seeley J; Weiss H; Khoo S; Chiodi F; Gray CM; Kaleebu P; Webb EL; Martinson N; Fox J;
EBioMedicine; 2023 Jul; 93():104648. PubMed ID: 37327677
[TBL] [Abstract][Full Text] [Related]
19. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Yager J; Castillo-Mancilla J; Ibrahim ME; Brooks KM; McHugh C; Morrow M; McCallister S; Bushman LR; MaWhinney S; Kiser JJ; Anderson PL
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):323-330. PubMed ID: 32539288
[TBL] [Abstract][Full Text] [Related]
20. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Imaz A; Niubó J; Cottrell ML; Perez E; Kashuba ADM; Tiraboschi JM; Morenilla S; Garcia B; Podzamczer D
Clin Infect Dis; 2019 Sep; 69(8):1403-1409. PubMed ID: 30561517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
